8月4日，映恩生物-B盘中上涨5.15%，报189.8港元，成交额1.3亿港元。此前该股因GSK竞争压力连续调整，7月30日大跌13.7%，8月3日再跌5.23%，当前出现明显反弹。
消息面上，药明康德半年报业绩超预期并全面上调全年指引，显著提振创新药产业链信心，港股通创新药ETF整体走强，映恩生物-B受板块情绪带动。此外，公司核心管线B7-H3 ADC Elfe-D近期获NMPA突破性疗法认定，海内外均获监管认可，多家券商给予"买入"评级，基本面支撑逐步修复市场信心。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.